

Supporting Information

Sai Ruan, Xia Zhong, Quangang Chen, Xiaoming Feng, and Xiaohua Liu*

Key Laboratory of Green Chemistry & Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu 610064, China.

E-mail: liuxh@scu.edu.cn


Table of Contents

1. General information.....	S2
2. Typical procedure for guanidines preparation.....	S2
3. Optimization of the reaction conditions.....	S3
4. Substrate scope of the reaction.....	S9
5. Attempts of other Michael acceptors.....	S11
6. Typical procedure for the four-component reaction.....	S11
7. The analytical and spectral characterization data of the products.....	S12
8. NMR spectra.....	S40
9. X-ray crystal structure of the product 3aa	S74
10. Copies of the CD spectra of the products.....	S75
11. References.....	S84

1. General information

¹H NMR spectra were recorded on commercial instruments (400 MHz). Chemical shifts were reported in ppm from tetramethylsilane with the solvent resonance as the internal standard (CDCl_3 , $\delta = 7.26$), and spectra were reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constants (Hz), integration and assignment. ¹³CNMR spectra were collected on commercial instruments (100 MHz) with complete proton decoupling. Enantiomeric excesses (*ee*) were determined by HPLC or UPC² analysis using the corresponding commercial chiralpak column as stated in the experimental procedures at 35 °C. Optical rotations were reported as follows: $[\alpha]_D^{18}$ (*c*: g/100 mL, in solvent). HRMS was recorded on a commercial apparatus (ESI Source). All catalytic reactions were run in dried glassware. THF, toluene and diethyl ether (Et_2O) were distilled from sodium benzophenone ketyl. Ethyl acetate, CH_2Cl_2 was distilled over CaH_2 .

2. Typical procedure for guanidines preparation




A solution of sulfonyl chloride **B** (10 mmol) was slowly added to a stirred solution of diamine **A** (10 mmol), NEt_3 (11 mmol) in dichloromethane (25 mL). The resulting mixture was stirred for another 2 hours, washed twice with water (25 mL) and dried over Na_2SO_4 . The solvent was removed *in vacuo* to give a white solid **C**. To a solution of *N*-Boc protected *L*-Proline **D** in CH_2Cl_2 (40 mL) was added NEt_3 (11 mmol), isobutyl carbonochloride (11 mmol) at 0 °C under stirring. After 10 min, **C** was added. The reaction was allowed to warm to room temperature for another 2 hours. The mixture was washed with 1 N KHSO_4 solution, saturated NaHCO_3 solution, and brine, dried over anhydrous Na_2SO_4 and concentrated to get a white solid **E**. Then, TFA (10 mL) was added to the CH_2Cl_2 (10 mL) solution of **E**, and stirred until the reaction finished (1-2 h). The pH value of the mixture was brought into the range of 10–12 by the addition of 2 N NaOH solution. The aqueous phase was extracted with CH_2Cl_2 (3×30 mL). The combined organic phase was washed with brine, dried over anhydrous Na_2SO_4 and concentrated and purified through flash chromatograph as a white solid **F** (40% yield).

nBuLi (2.4 M in *n*-hexane, 3.3 eq., 13.2 mmol) was injected into a solution of **F** (4.0 mmol) in THF (30 mL) dropwise over 10 min under nitrogen atmosphere at –20 °C with well stirring. After additional 10 min, a solution of *N,N*-dicyclohexylcarbodiimide (1.2 eq., 4.8 mmol) in 10 mL of THF was added

dropwise within 10 min. The reaction was allowed to warm to room temperature and detected by TLC. After 16 h, the mixture was evaporated under reduced pressure to get rid of THF, and the pH value of the mixture was brought into the range of 0–1 by the addition of 3 M HBr. The aqueous phase was extracted with CH_2Cl_2 (3×10 mL), washed with water, dried over anhydrous Na_2SO_4 and evaporated in vacuum, and purified through flash chromatograph on silica gel to produce guanidinium salt **G**. The purified guanidinium salt **G** (46% yield) can be given through recrystallization in CHCl_3 and n-Hexane. Then, guanidinium salt **G** in CH_2Cl_2 (20 mL) was added 5 M NaOH (20 mL) and stirred until the basification finished (10 mins). The pH value of the mixture was kept in the range of 11–12. The aqueous phase was extracted with CH_2Cl_2 (5×20 mL). The combined organic phase was washed with 5 M NaOH, dried over anhydrous Na_2SO_4 and evaporated in vacuum. Finally, a white solid was obtained. Then it was dissolved in CH_2Cl_2 and filtration through Celite to remove the silicone gel, concentrate to get a kind of white foam. For other catalysts, the synthesis method could be found in the literature.¹

3. Optimization of the reaction conditions


Table 1: Screening of guanidines^[a]



entry	cat	yield (%) ^[b]	dr ^[c]	ee (%) ^[c]
1	G-1	21	94:6	8/5
2	G-2	18	>19:1	31
3	G-3	13	84:16	5/11
4	G-4	40	88:12	49/33
5	G-5	46	88:12	67/43
6	G-6	51	88:12	50/22
7	G-7	39	91:9	48/17
8	G-8	42	86:14	53/30
9	G-9	55	88:12	52/27
10	G-10	49	88:12	45/17
11	G-11	26	90:10	5/5
12	G-12	15	91:9	9/5
13	G-13	29	83:17	0/0
14	G-14	19	87:13	13/5

[a] Unless otherwise noted, all reactions were carried out with guanidine (10 mol%), CuCl(100 mol%), **1a** (0.10 mmol), TMSCN (0.10 mmol) and MeOH (0.10 mmol) in CH₂Cl₂ (0.5 mL) at 30 °C for 2 h, then **2a** (0.10 mmol) was added at 30 °C and reacted at 30 °C for 12 h. [b] Isolated yield. [c] Determined by HPLC analysis.


Table 2: Screening of the copper salt^[a]



entry	CuX	yield (%) ^[b]	dr ^[c]	ee (%) ^[c]
1	CuCl	46	88:12	67/43
2	CuBr	60	88:12	73/47
3	CuI	5	80:20	0/0
4	CuBr•SMe ₂	trace	nd	nd
5	Cu(MeCN) ₄ PF ₆	trace	nd	nd
6	Cu(MeCN) ₄ BF ₄	trace	nd	nd

[a] Unless otherwise noted, all reactions were carried out with **G-5** (10 mol%), copper salts (100 mol%), **1a** (0.10 mmol), TMSCN (0.10 mmol) and MeOH (0.10 mmol) in CH₂Cl₂ (0.5 mL) at 30 °C for 2 h, then **2a** (0.10 mmol) was added at 30 °C and reacted at 30 °C for 12 h. [b] Isolated yield. [c] Determined by HPLC analysis. nd: not detected.

Table 3: Screening of the solvents^[a]



entry	solvent	yield (%) ^[b]	dr ^[c]	ee (%) ^[c]
1	Toluene	trace	nd	nd
2	THF	trace	nd	nd

3	CH ₂ Cl ₂	60	88:12	73/47
3	CHCl ₃	43	86:14	65/43
4	AcOEt	nr	nd	nd
5	CH ₃ CN	nr	nd	nd
6	Et ₂ O	trace	nd	nd

[a] Unless otherwise noted, all reactions were carried out with **G-5** (10 mol%), CuBr (100 mol%), **1a** (0.10 mmol), TMSCN (0.10 mmol) and MeOH (0.10 mmol) in solvent (0.5 mL) at 30 °C for 2 h, then **2a** (0.10 mmol) was added at 30 °C and reacted at 30 °C for 12 h. [b] Isolated yield. [c] Determined by HPLC analysis. nd: not detected, nr: no reaction.

Table 4: Screening the amount of copper salt and additives ^[a]

1a		2a	3aa		
entry	CuBr [x mol%]	Additive [mg]	yield (%) ^[b]	dr ^[c]	ee (%) ^[c]
1	100	-	60	88:12	73/47
2 ^[d]	50	-	65	89:11	73/49
3 ^[e]	50	-	71	88:12	74/49
4 ^[e]	40	-	66	88:12	74/49
5 ^[e]	30	-	trace	nd	nd
6 ^[e]	30	5 Å MS (20)	83	89:11	73/49
7 ^[e]	20	5 Å MS (20)	85	88:12	74/47
8 ^[e]	20	4 Å MS (20)	trace	nd	nd
9 ^[e]	20	3 Å MS (20)	trace	nd	nd
10 ^[e]	15	5 Å MS (20)	trace	nd	nd
11 ^[e]	10	5 Å MS (20)	trace	nd	nd
12 ^[f]	15	5 Å MS (20)+YB ₃ (1.7)	trace	nd	nd
13 ^[g]	15	5 Å MS (20)+HBr (5 mol%)	trace	nd	nd

[a] Unless otherwise noted, all reactions were carried out with **G-5** (10 mol%), CuBr(x mol%), **1a** (0.10 mmol), TMSCN (0.10 mmol) and MeOH (0.10 mmol) in CH₂Cl₂ (0.5 mL) at 30 °C for 2 h, then **2a** (0.10 mmol) was added at 30 °C for 12 h. [b] Isolated yield. [c] Determined by HPLC analysis. [d] **G-5** HCl (10 mol%). [e] **G-5** HBr (10 mol%). [f] YB₃ (5 mol%: 1.7 mg). [g] HBr (5 mol%: 1.0 M, 5.0 uL).

Table 5: Screening of the temperature^[a]

1a	2a	3aa		
G-5 •HBr (10 mol%) CuBr (20 mol%) 5 Å MS, CH ₂ Cl ₂ , 30 °C, 2h, Then T, 24h,				
entry	T (°C)	yield (%) ^[b]	dr ^[c]	ee (%) ^[c]
1	0	67	95:5	87
2	-10	62	96:4	90
3	-20	61	96:4	92
4	-30	65	96:4	95
5	-40	62	96:4	96

[a] Unless otherwise noted, all reactions were carried out with **G-5 HBr** (10 mol%), CuBr (20 mol%), 5 Å MS (20 mg), **1a** (0.10 mmol), TMSCN (0.10 mmol) and MeOH (0.10 mmol) in CH₂Cl₂ (0.5 mL) at 30 °C for 2 h, then **2a** (0.10 mmol) was added at the corresponding temperature and reacted for 24 h. [b] Isolated yield. [c] Determined by HPLC analysis.

Table 6: Screening of the alcohols^[a]

1a	2a	3aa		
G-5 •HBr (10 mol%) CuBr (20 mol%) 5 Å MS, CH ₂ Cl ₂ , 30 °C, 2h, Then -30 °C, 24h,				
entry	ROH	yield (%) ^[b]	dr ^[c]	ee (%) ^[c]
1	MeOH	65	96:4	95
2	<i>i</i> PrOH	60	96:4	95
3	<i>t</i> BuOH	80	96:4	95
4	CF ₃ CH ₂ OH	trace	nd	nd
5	H ₂ O	60	95:5	95
6	HFIP	trace	nd	nd
7	Benzoic Acid	nr	—	—
8	Phenol	nr	—	—
9	—	nr	—	—

[a] Unless otherwise noted, all reactions were carried out with **G-5 HBr** (10 mol%), CuBr (20 mol%), 5 Å MS (20 mg), **1a** (0.10 mmol), TMSCN (0.10 mmol) and alcohol (0.10 mmol) in CH₂Cl₂ (0.5 mL) at 30 °C for 2 h, then **2a** (0.10 mmol) was added at -30 °C and reacted at -30 °C for 24 h. [b] Isolated yield.

[c] Determined by HPLC analysis. HFIP: Hexafluoroisopropanol.

Table 7: Screening of the substrate ratio^[a]

entry	1a:TMSCN:^tBuOH:2a	yield (%) ^[b]	dr ^[c]
1	1:1:1:1	80	96:4
2	1.2:1.2:1.2:1	86	96:4
3	1.4:1.4:1.4:1	87	96:4
4 ^[d]	1.2:1.2:1.2:1	77	97:3
		ee (%) ^[c]	
		95	
		95	
		95	
		95	

[a] Unless otherwise noted, all reactions were carried out with **G-5** •HBr (10 mol%), CuBr (20 mol%), 5 Å MS (20 mg), **1a**, TMSCN, and ^tBuOH in CH₂Cl₂ (0.5 mL) at 30 °C for 2 h, then **2a** (0.10 mmol) was added at -30 °C and reacted at -30 °C for 24 h. [b] Isolated yield. [c] Determined by HPLC analysis. [d] CH₂Cl₂ (1.0 mL).

Table 8: Control experiments A^[a]





Table 9: Control experiments B



Method 1: CuBr (20 mol%) and 5 Å MS (20 mg) were added into the test tube, then under the protection of nitrogen, CH₂Cl₂ (0.5 mL) was added. Then the ^tBuOH (0.12 mmol), TMSCN (0.12

mmol) and α -diazoester **1a** (0.12 mmol) were added in sequence to the reaction which were stirred at 30 °C for 2 h. Subsequently, the reaction mixture was stirred at –30 °C for 5 min, *N*-phenyl maleimide **2a** (0.10 mmol) and catalyst **G-5** (10 mol%) dissolved in 0.2 mL of CH₂Cl₂ were added to the reaction. After the mixture was stirred at –30 °C for 24 h. Isolated yield. Ee and dr values were determined by UPC² analysis.

Method 2: The reactions were carried out with CuBr (20 mol%) and 5 Å MS (20 mg) were added into the test tube, then under the protection of nitrogen, CH₂Cl₂ (0.5 mL) was added. Then the ¹BuOH (0.12 mmol), TMSCN (0.12 mmol) and α -diazoester **1a** (0.12 mmol) were added in sequence to the reaction which were stirred at 30 °C for 2 h. Subsequently, the reaction mixture was stirred at –30 °C for 5 min, *N*-phenyl maleimide **2a** (0.10 mmol) and catalyst **G-5** HBr (10 mol%) dissolved in 0.2 mL of CH₂Cl₂ were added to the reaction. After the mixture was stirred at –30 °C for 24 h. Isolated yield. Ee and dr values were determined by UPC² analysis.

4. Substrate scope

Table 9: Substrate scope of α -aryl diazoacetates **1**^[a]

entry	1: Ar	R ₁	Additives	Yield (%) ^b	3	
					dr ^c	ee (%) ^c
1	1a: Ph	Me	5 Å MS (20 mg)	86 (3aa)	13:1	95
2	1b: Ph	Et	5 Å MS (20 mg)	81 (3ba)	13:1	96
3	1c: Ph	'Pr	5 Å MS (20 mg)	68 (3ca)	13:1	96
4	1d: Ph	'Bu	5 Å MS (20 mg)	trace (3da)	nd	nd
5	1e: 2-FC ₆ H ₄	Me	DABCO (50 mol%)	75 (3ea)	2:1	85/70
6 ^d	1f: 3-MeC ₆ H ₄	Me	DABCO (30 mol%)	87 (3fa)	13:1	89
7	1g: 4-MeC ₆ H ₄	Me	5 Å MS (20 mg)	71 (3ga)	13:1	95
8	1h: 4-MeOC ₆ H ₄	Me	DABCO (30 mol%)	68 (3ha)	13:1	93
9	1i: 4-FC ₆ H ₄	Me	5 Å MS (20 mg)	80 (3ia)	>19:1	93
10 ^e	1j: 4-ClC ₆ H ₄	Me	DABCO (30 mol%)	74(90) ^f (3ja)	>19:1	78(91) ^f
11 ^e	1k: 4-BrC ₆ H ₄	Me	DABCO (30 mol%)	69(74) ^f (3ka)	>19:1	72(92) ^f
12 ^e	1l: 4-IC ₆ H ₄	Me	DABCO (30 mol%)	59(70) ^f (3la)	>19:1	70(88) ^f
13 ^g	1m: 2-naphthyl	Me	DABCO (30 mol%)	99 (3ma)	15:1	92


[a] unless otherwise noted, all reactions were carried out with **G-5 HBr** (10 mol%), CuBr (20 mol%), 5 Å MS, **1** (1.2 equiv), TMSCN (1.2 equiv) and ^tBuOH (1.2 equiv) in CH₂Cl₂ (0.5 mL) at 30 °C for 2 h, then **2a** (0.10 mmol) and DABCO were added at -30 °C and reacted at -30 °C for 24 h. [b] Isolated yield. [c] Determined by UPC² and NMR analysis. [d] CuBr•SMe₂ (20 mol%). [e] **1a**/TMSCN/^tBuOH/**2a** (1.4/1.4/1.4/1), CuBr (40 mol%); [f] Date in parentheses was used CuBr (100 mol%), and DABCO (0.5 equiv). [g] CuBr (50 mol%), and at -30 °C for 12 h.

Table 10: Substrate scope of *N*-substituted maleimides **2**^[a]

entry	2: R ₂	yield (%) ^[b]	dr ^[c]	ee (%) ^[c]
1	4-MeC ₆ H ₄	62 (3ab)	>19:1	92
2	4-MeOC ₆ H ₄	70 (3ac)	16:1	92
3	4-EtC ₆ H ₄	73 (3ad)	>19:1	93
4	4-EtOC ₆ H ₄	65 (3ae)	>19:1	93
5	4-iPrC ₆ H ₄	72 (3af)	>19:1	92
6	4-FC ₆ H ₄	78 (3ag)	19:1	92
7	4-ClC ₆ H ₄	68 (3ah)	16:1	93
8	4-BrC ₆ H ₄	65 (3ai)	16:1	93
9	4-IC ₆ H ₄	78 (3aj)	16:1	93
10	2-FC ₆ H ₄	73 (3ak)	11:1	93
11	2-MeC ₆ H ₄	85 (3al)	60:40	92
12	3-FC ₆ H ₄	65 (3am)	16:1	91
13	Bn	36 (3an)	7:1	72
14	Me	54 (3ao)	5:1	50
15	H	nr (3ap)	—	—

[a] Unless otherwise noted, the reactions were carried out **G-5** HBr (10 mol%), 5 Å MS (20 mg), **1a** (0.12 mmol), TMSCN (0.12 mmol) and ¹BuOH (0.12 mmol) in CH₂Cl₂ (0.5 mL) at 30 °C for 2 h, then **2** (0.10 mmol) was added at -30 °C and reacted at -30 °C for 24 h. [b] Isolated yield. [c] Determined by UPC² and NMR analysis .

5. Attempts of other Electrophiles




6. Typical procedure for the reaction


CuBr (2.9 mg, 20 mol%), catalyst **G-5** + HBr (7.8 mg, 10 mol%) and 5 Å MS (20 mg) were added into the test tube, then under the protection of nitrogen, CH₂Cl₂ (0.5 mL) was added. Then the ^tBuOH (0.12 mmol, 12.0 uL), TMSCN (0.12 mmol, 16.0 uL) and α -diazoester **1a** (0.12 mmol, 20.5 uL) were added in sequence to the reaction which were stirred at 30 °C for 2 h. Subsequently, the reaction mixture was stirred at -30 °C for 5 min, *N*-phenyl maleimide **2a** (0.10 mmol, 17.3 mg) and DABCO (0-50 mol%) dissolved in 0.2 mL of CH₂Cl₂ were added to the reaction. After the mixture was stirred at -30 °C for 24 h, it was purified by silica gel column chromatography (ethyl acetate/petroleum ether/CH₂Cl₂ 1/4/1) to afford the desired product. Then the purified product was used for HPLC or UPC² analysis.

7. The analytical and spectral characterization data of the product


Methyl (*R*)-2-cyano-2-[*(S*)-2,5-dioxo-1-phenylpyrrolidin-3-yl]-2-phenylacetate (3aa)



White solid, 85% yield, 13:1 dr, 95% ee, mp: 125–129 °C. $[\alpha]_D^{23} = -54.5$ (c: 0.54, CH_2Cl_2); Determined by HPLC analysis [Daicel chiralcel IB, n-Hexane/ $i\text{PrOH}$ = 70/30, 1.0 mL/min, $\lambda = 230.0$ nm, t (major_{isomer}) = 10.88 min, 14.61 min; t (minor_{isomer}) = 17.33, 20.71 min]; ^1H NMR (400 MHz, CDCl_3) δ 7.71 – 7.59 (m, 2H), 7.53 – 7.38 (m, 6H), 7.35 – 7.28 (m, 2H), 4.41 (dd, $J = 9.2, 6.4$ Hz, 1H), 3.88 (s, 3H), 2.82 (dd, $J = 18.8, 9.6$ Hz, 1H), 2.55 (dd, $J = 18.4, 6.4$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 174.0, 172.8, 166.6, 131.2, 131.1, 130.0, 129.8, 129.3, 129.1, 126.5, 115.8, 55.3, 54.7, 47.1, 31.6. HRMS (ESI-FT) calcd for $\text{C}_{20}\text{H}_{16}\text{N}_2\text{O}_4\text{K}^+$ ($\mathbf{M}+\mathbf{K}$)⁺, m/z: 387.0742, observed: 387.0737. IR: 1750, 1715, 1500, 1387, 1244, 1193, 695, 623 cm^{-1} .




	Retention Time	Area	% Area
1	10.170	5462740	40.76
2	13.696	5469977	40.81
3	16.194	1242043	9.27
4	19.334	1228520	9.17




	Retention Time	Area	% Area
1	10.882	4487906	93.76
2	14.614	114802	2.40
3	17.326	162423	3.39
4	20.713	21366	0.45


Ethyl 2-cyano-2-[2,5-dioxo-1-phenylpyrrolidin-3-yl]-2-phenylacetate (3ba)



Colorless oily, 81% yield, 13:1 dr, 96% ee, $[\alpha]_D^{23} = -52.3$ ($c: 0.53$, CH_2Cl_2); Determined by HPLC analysis [Daicel chiralcel ADH, *n*-Hexane/ i PrOH = 70/30, 1.0 mL/min, $\lambda = 254.0$ nm, t (major_{isomer}) = 24.52 min, 38.85 min; t (minor_{isomer}) = 13.11, 17.75 min]; ^1H NMR (400 MHz, CDCl_3) δ 7.70 – 7.61 (m, 2H), 7.51 – 7.38 (m, 6H), 7.35 – 7.27 (m, 2H), 4.43 – 4.34 (m, 2H), 4.31 – 4.23 (m, 1H), 2.80 (dd, $J = 18.8, 9.6$ Hz, 1H), 2.65 (dd, $J = 18.4, 6.4$ Hz, 1H), 1.31 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 174.0, 172.9, 166.0, 131.2, 129.9, 129.7, 129.3, 129.1, 126.6, 126.5, 115.9, 64.2, 55.5, 47.0, 31.7, 13.8. HRMS (ESI-FT) calcd for $\text{C}_{21}\text{H}_{18}\text{N}_2\text{O}_4\text{Na}^+$ ($\mathbf{M}+\text{Na}$)⁺, m/z: 385.1159, observed: 385.1169. IR: 1745, 1717, 1499, 1386, 1237, 1191, 1023, 730, 694 cm^{-1} .




	Retention Time	Area	% Area
1	13.358	1911979	8.74
2	18.053	1927429	8.85
3	25.866	9058756	41.40
4	39.314	8972201	41.01




	Retention Time	Area	% Area
1	13.111	426616	4.72
2	17.748	47087	0.52
3	24.519	233550	2.58
4	38.849	8333312	92.18


Isopropyl 2-cyano-2-[2,5-dioxo-1-phenylpyrrolidin-3-yl]-2-phenylacetate (3ca)



Colorless oily, 68% yield, 13:1 dr, 96% ee, $[\alpha]_D^{23} = -45.2$ ($c: 0.46$, CH_2Cl_2); Determined by HPLC analysis [Daicel chiralcel IB, *n*-Hexane /ⁱPrOH = 75/25, 1.0 mL/min, $\lambda = 254$ nm, t (major_{isomer}) = 10.73, 15.40 min, t (minor_{isomer}) = 14.26, 19.41 min]; ¹H NMR (400 MHz, CDCl_3) δ 7.68 – 7.60 (m, 2H), 7.51 – 7.39 (m, 6H), 7.34 – 7.28 (m, 2H), 5.19 – 5.05 (m, 1H), 4.50 – 4.28 (m, 1H), 2.86 – 2.73 (dd, $J = 18.4, 9.2$ Hz, 1H), 2.61 – 2.45 (dd, $J = 18.8, 6.8$ Hz, 1H), 1.36 (d, $J = 6.4$ Hz, 2H), 1.21 (d, $J = 6.0$ Hz, 2H). ¹³C NMR (100 MHz, CDCl_3) δ 173.9, 172.9, 165.4, 131.4, 131.3, 129.9, 129.7, 129.3, 129.1, 126.6, 126.5, 116.0, 72.5, 55.7, 46.8, 31.7, 21.4, 21.3. HRMS (ESI-FT) calcd for $\text{C}_{22}\text{H}_{20}\text{N}_2\text{O}_4\text{Na}^+$ (**M+Na**)⁺, m/z: 399.1315, observed: 399.1309. IR: 1749, 1715, 1490, 1386, 1244, 1179, 1070, 1014, 826, 731, 695 cm^{-1} .




	Retention Time	Area	% Area
1	10.752	21862603	43.63
2	14.164	2794838	5.58
3	14.672	22251187	44.41
4	19.165	3196963	6.38




	Retention Time	Area	% Area
1	10.734	4419091	92.21
2	14.260	261732	5.46
3	15.405	87786	1.83
4	19.408	23611	0.49


Methyl 2-cyano-2-(2,5-dioxo-1-phenylpyrrolidin-3-yl)-2-(2-fluorophenyl)acetate (3ea)



Colorless oily, 75% yield, 2:1 dr, 85/70% ee, $[\alpha]_D^{25} = -22.3$ ($c: 0.89$, CH_2Cl_2); Determined by UPC² analysis [Daicel chiralcel OX-3, scCO₂/PrOH = 90/10, 1.5 mL/min, $\lambda = 229.0$ nm, t (major_{isomer}) = 7.45, 9.82, t (minor_{isomer}) = 9.32, 11.35 min]; ¹H NMR (400 MHz, CDCl₃) δ 7.64 – 7.37 (m, 5H), 7.31 – 7.25 (m, 3H), 7.22 – 7.12 (m, 1H), 4.50 (dd, $J = 9.6, 6.0$ Hz, 1H), 3.90 (s, 3H), 3.13 (dd, $J = 18.4, 9.6$ Hz, 1H), 2.71 (dd, $J = 18.4, 6.0$ Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 173.8, 173.0, 165.5, 161.1 ($J = 249.6$ Hz, 1C), 158.6, 132.3 ($J = 22.9$ Hz, 1C), 131.3, 129.9 ($J = 2.2$ Hz, 1C), 129.3 ($J = 2.2$ Hz, 1C), 126.5, 125.4, 119.0 ($J = 7.8$ Hz, 1C), 117.6 ($J = 22.4$ Hz, 1C), 115.7, 54.8, 52.9, 44.9, 32.3. ¹⁹F NMR (376 MHz, CDCl₃) δ -110.4 (s, 1F). HRMS (ESI-FT) calcd for [M+Na]⁺ C₂₀H₁₅FN₂O₄Na⁺, m/z: 389.0908, observed: 389.0904. IR: 1754, 1720, 1494, 1389, 1264, 1193, 896, 732, 703 cm⁻¹.




	Retention Time	Area	% Area
1	7.345	2306081	29.87
2	9.262	1579427	20.46
3	9.833	2225581	28.83
4	11.211	1608789	20.84




	Retention Time	Area	% Area
1	7.451	744249	4.66
2	9.318	4144402	25.95
3	9.820	10327444	64.66
4	11.350	756454	4.74


Methyl 2-cyano-2-[2,5-dioxo-1-phenylpyrrolidin-3-yl]-2-(3-methoxyphenyl)acetate (3fa)



White solid, 87% yield, 13:1 dr, 90% ee, mp: 82–84 °C. $[\alpha]_D^{24} = -55.9$ (*c*: 0.54, CH_2Cl_2); Determined by UPC² analysis [Daicel chiralcel OX-3, scCO₂/PrOH = 90/10, 1.5 mL/min, $\lambda = 233.0$ nm, t (major_{isomer}) = 5.04, 5.95 min, t (minor_{isomer}) = 11.42, 12.43 min]; ¹H NMR (400 MHz, CDCl_3) δ 7.51 – 7.37 (m, 5H), 7.36 – 7.24 (m, 4H), 4.40 (dd, *J* = 9.6, 6.4 Hz, 1H), 3.88 (s, 3H), 2.82 (dd, *J* = 18.8, 9.6 Hz, 1H), 2.55 (dd, *J* = 18.8, 6.4 Hz, 1H), 2.41 (s, 3H). ¹³C NMR (100 MHz, CDCl_3) δ 174.1, 172.9, 166.6, 139.8, 131.2, 130.9, 130.8, 129.6, 129.3, 129.1, 127.1, 126.5, 123.5, 115.9, 55.2, 54.6, 47.7, 31.7, 21.6. HRMS (ESI-FT) calcd for $[\text{M}+\text{Na}]^+$ $\text{C}_{21}\text{H}_{18}\text{N}_2\text{O}_4\text{Na}^+$, m/z: 385.1159, observed: 385.1157. IR: 1750, 1716, 1500, 1387, 1263, 1191, 734, 699 cm^{-1} .




	Retention Time	Area	% Area
1	4.984	2645648	39.35
2	6.021	2666564	39.66
3	11.238	701030	10.43
4	12.353	710731	10.57




	Retention Time	Area	% Area
1	4.953	328087	4.89
2	5.942	6076977	90.63
3	11.162	72050	1.07
4	12.120	228006	3.40

Methyl -2-cyano-2-(2,5-dioxo-1-phenylpyrrolidin-3-yl)-2-(p-tolyl)acetate (3ga)




White solid, 71% yield, 13:1 dr, 95% ee, mp: 150–154 °C. $[\alpha]_D^{16} = -89.7$ (*c*: 0.14, CH_2Cl_2); Determined by UPC² analysis [Daicel chiralcel OX-3, scCO₂/PrOH = 90/10, 1.5 mL/min, $\lambda = 218.0$ nm, t (major_{isomer}) = 6.16, 6.94 min, t (minor_{isomer}) = 14.27, 16.00 min]; ¹H NMR (400 MHz, CDCl_3) δ 7.56 – 7.38 (m, 5H), 7.33 – 7.25 (m, 4H), 4.38 (dd, *J* = 9.6, 6.4 Hz, 1H), 3.87 (s, 3H), 2.82 (dd, *J* = 18.8, 9.6 Hz, 1H), 2.55 (dd, *J* = 18.4, 6.4 Hz, 1H), 2.39 (s, 3H).

¹³C NMR (100 MHz, CDCl_3) δ 174.0, 172.9, 166.8, 140.2, 131.2, 130.4, 129.3, 129.1, 128.1, 126.5, 126.4, 115.9, 55.0, 54.6, 47.0, 31.6, 21.1. HRMS (ESI-FT) calcd for $[\text{M}+\text{Na}]^+$ $\text{C}_{21}\text{H}_{18}\text{N}_2\text{O}_4\text{Na}^+$, m/z: 385.1159, observed: 385.1163. IR: 1748, 1713, 1501, 1388, 1243, 1193, 1019, 694 cm^{-1} .




	Retention Time	Area	% Area
1	6.124	15289599	39.32
2	7.081	15333483	39.44
3	14.073	4139311	10.65
4	15.955	4118060	10.59




	Retention Time	Area	% Area
1	6.165	715219	2.50
2	6.935	26891083	93.88
3	14.270	174932	0.61
4	15.997	864105	3.02


Methyl -2-cyano-2-(2,5-dioxo-1-phenylpyrrolidin-3-yl)-2-(4-methoxyphenyl)acetate (3ha)



White solid, 68% yield, 13:1 dr, 93% ee, mp: 145–147 °C. $[\alpha]_D^{24} = -68.0$ (*c*: 0.53, CH_2Cl_2); Determined by UPC² analysis [Daicel chiralcel OX-3, scCO₂/PrOH = 90/10, 1.5 mL/min, $\lambda = 234.0$ nm, t (major_{isomer}) = 8.07, 9.82 min, t (minor_{isomer}) = 17.03, 23.95 min]; ¹H NMR (400 MHz, CDCl_3) δ 7.60 – 7.38 (m, 5H), 7.33 – 7.28 (m, 2H), 7.02 – 6.92 (m, 2H), 4.36 (dd, *J* = 9.6, 6.4 Hz, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 2.82 (dd, *J* = 18.8, 9.6 Hz, 1H), 2.55 (dd, *J* = 18.8, 6.4 Hz, 1H). ¹³C NMR (100 MHz, CDCl_3) δ 174.0, 172.9, 166.9, 160.7, 131.2, 129.3, 129.1, 127.8, 126.5, 126.2, 116.0, 115.0, 55.5, 54.7, 54.5, 47.1, 31.6. HRMS (ESI-FT) calcd for [M+Na]⁺ $\text{C}_{21}\text{H}_{18}\text{N}_2\text{O}_5\text{Na}^+$, m/z: 401.1108, observed: 401.1107. IR: 1748, 1714, 1608, 1511, 1389, 1260, 1186, 1029, 747, 697 cm^{-1} .




	Retention Time	Area	% Area
1	7.609	4306811	40.51
2	9.235	4317786	40.61
3	16.093	1039100	9.77
4	22.433	967979	9.10




	Retention Time	Area	% Area
1	8.069	513137	3.19
2	9.823	14753883	91.81
3	17.031	315565	1.96
4	23.946	487872	3.04


Methyl 2-cyano-2-[2,5-dioxo-1-phenylpyrrolidin-3-yl]-2-(4-fluorophenyl)acetate (3ia)



White solid, 80% yield, >19:1 dr, 93% ee, mp: 160–162 °C. $[\alpha]_D^{16} = -46.2$ (*c*: 0.42, CH_2Cl_2); Determined by HPLC analysis [Daicel chiralcel IB, *n*-Hexane/ i PrOH = 70/30, 1.0 mL/min, λ = 254 nm, t (major_{isomer}) = 9.91, 14.38 min, t (minor_{isomer}) = 17.04, 18.85 min]; ^1H NMR (400 MHz, CDCl_3) δ 7.71 – 7.60 (m, 2H), 7.53 – 7.39 (m, 3H), 7.35 – 7.28 (m, 2H), 7.23 – 7.13 (m, 2H), 4.35 (dd, *J* = 9.6, 6.8 Hz, 1H), 3.89 (s, 3H), 2.83 (dd, *J* = 18.4, 9.6 Hz, 1H), 2.54 (dd, *J* = 18.4, 6.4 Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 173.8, 172.6, 166.5, 164.7 (*J* = 249.8 Hz, 1C), 131.1, 129.3 (*J* = 8.2 Hz, 1C), 129.2, 128.7 (*J* = 8.5 Hz, 1C), 126.9 (*J* = 3.3 Hz, 1C), 126.5, 117.0 (*J* = 22 Hz, 1C), 115.7, 54.7, 54.7, 47.2, 31.6. ^{19}F NMR (376 MHz, CDCl_3) δ -110.4 (s, 1F). HRMS (ESI-FT) calcd for $[\text{M}+\text{Na}]^+$ $\text{C}_{20}\text{H}_{15}\text{FN}_2\text{O}_4\text{Na}^+$, m/z: 389.0908, observed: 389.0907. IR: 2360, 2341, 1752, 1717, 1509, 1390, 1263, 734, 700 cm^{-1} .




	Retention Time	Area	% Area
1	11.181	5130085	44.57
2	14.901	5105901	44.36
3	18.811	653612	5.68
4	20.896	621565	5.40




	Retention Time	Area	% Area
1	10.999	19283257	93.89
2	15.269	731013	3.56
3	18.534	512041	2.49
4	21.155	11380	0.06


Methyl 2-cyano-2-[2,5-dioxo-1-phenylpyrrolidin-3-yl]-2-(4-chlorophenyl)acetate (3ja)




White solid, 90% yield, >19:1 dr, 91% ee, mp: 75–78 °C. $[\alpha]_D^{24} = -60.7$ (*c*: 0.57, CH_2Cl_2); Determined by UPC² analysis [Daicel chiralcel OJ-3, scCO₂/MeOH = 90/10, 1.5 mL/min, $\lambda = 233.0$ nm, *t* (major_{isomer}) = 5.14 min, *t* (minor_{isomer}) = 7.18 min]; ¹H NMR (400 MHz, CDCl_3) δ 7.65 – 7.55 (m, 2H), 7.51 – 7.39 (m, 5H), 7.34 – 7.27 (m, 2H), 4.35 (dd, *J* = 9.6, 6.4 Hz, 1H), 3.88 (s, 3H), 2.82 (dd, *J* = 18.4, 9.6 Hz, 1H), 2.52 (dd, *J* = 18.8, 6.4 Hz, 1H). ¹³C NMR (100 MHz, CDCl_3) δ 173.8, 172.6, 166.4, 136.5, 131.1, 130.0, 129.6, 129.4, 129.2, 128.0, 126.5, 115.5, 54.8, 47.1, 31.5. HRMS (ESI-FT) calcd for [M+Na]⁺ $\text{C}_{20}\text{H}_{15}\text{ClN}_2\text{O}_4\text{Na}^+$, m/z: 405.0613, 407.0583, observed: 405.0612, 407.0580. IR: 1750, 1714, 1495, 1388, 1263, 1195, 1097, 1015, 734, 699 cm⁻¹.



	Retention Time	Area	% Area
1	5.110	2575251	49.22
2	7.025	2657138	50.78




	Retention Time	Area	% Area
1	5.144	10545906	95.67
2	7.180	476811	4.33




	Retention Time	Area	% Area
1	5.218	10695785	89.07
2	7.240	1312694	10.93


Methyl 2-cyano-2-[2,5-dioxo-1-phenylpyrrolidin-3-yl]-2-(4-bromophenyl)acetate (3ka)




Colorless oily, 74% yield, >19:1 dr, 92% ee, $[\alpha]_D^{24} = -62.8$ ($c: 0.37$, CH_2Cl_2); Determined by UPC² analysis [Daicel chiralcel OJ-3, scCO₂/MeOH = 90/10, 1.5 mL/min, $\lambda = 235.0$ nm, t (major_{isomer}) = 6.52 min, t (minor_{isomer}) = 9.82 min]; ¹H NMR (400 MHz, CDCl₃) δ 7.66 – 7.58 (m, 2H), 7.56 – 7.39 (m, 5H), 7.35 – 7.27 (m, 2H), 4.34 (dd, $J = 9.6, 6.4$ Hz, 1H), 3.89 (s, 3H), 2.82 (dd, $J = 18.8, 9.6$ Hz, 1H), 2.52 (dd, $J = 18.8, 6.4$ Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 173.7, 172.5, 166.3, 133.0, 131.1, 130.1, 129.4, 129.2, 128.2, 126.5, 124.6, 115.4, 54.9, 54.8, 47.1, 31.5. HRMS (ESI-FT) calcd for [M+Na]⁺ C₂₀H₁₅BrN₂O₄Na⁺, m/z: 449.0107, 451.0087, observed: 449.0114, 451.0092. IR: 1750, 1715, 1492, 1389, 1261, 1197, 733, 698 cm⁻¹.



	Retention Time	Area	% Area
1	6.552	5729941	49.88
2	9.762	5756762	50.12




	Retention Time	Area	% Area
1	6.522	19823378	96.12
2	9.824	800139	3.88




	Retention Time	Area	% Area
1	6.504	16738518	86.17
2	9.783	2686045	13.83


Methyl -2-cyano-2-(2,5-dioxo-1-phenylpyrrolidin-3-yl)-2-(4-iodophenyl)acetate (3la)




Colorless oily, 70% yield, >19:1 dr, 88% ee, $[\alpha]_D^{25} = -63.5$ ($c: 0.38$, CH_2Cl_2); Determined by UPC² analysis [Daicel chiralcel OJ-3, scCO₂/MeOH = 90/10, 1.5 mL/min, $\lambda = 235.0$ nm, t (major_{isomer}) = 9.11, 9.87 min, t (minor_{isomer}) = 12.96, 19.10 min]; ¹H NMR (400 MHz, CDCl₃) δ 7.89 – 7.75 (m, 2H), 7.98 – 7.84 (m, 5H), 7.63 – 7.54 (m, 2H), 7.51 – 7.38 (m, 3H), 7.37 – 7.28 (m, 2H), 4.54 (dd, $J = 9.6, 6.4$ Hz, 1H), 3.88 (s, 3H), 2.81 (dd, $J = 18.8, 9.6$ Hz, 1H), 2.58 (dd, $J = 18.4, 6.4$ Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 173.7, 172.5, 166.2, 138.9, 131.1, 130.8, 129.3, 129.2, 128.3, 126.5, 115.4, 96.4, 55.0, 54.8, 47.0, 31.5. HRMS (ESI-FT) calcd for [M+Na]⁺ C₂₀H₁₅IN₂O₄Na⁺, m/z: 496.9969, observed: 496.9969. IR: 1750, 1715, 1500, 1389, 1262, 1196, 1007, 735, 698 cm⁻¹.



	Retention Time	Area	% Area
1	8.882	15103086	42.20
2	9.504	15308544	42.77
3	12.518	2700167	7.54
4	18.365	2679439	7.49




	Retention Time	Area	% Area
1	9.114	1240865	5.38
2	9.869	20465604	88.70
3	12.959	486425	2.11
4	19.104	880061	3.81




	Retention Time	Area	% Area
1	8.585	1613971	13.68
2	9.200	9334372	79.10
3	12.108	321235	2.72
4	17.914	530998	4.50


Methyl 2-cyano-2-[2,5-dioxo-1-phenylpyrrolidin-3-yl]-2-(2-naphthyl)acetate (3ja)



White solid, 99% yield, 15:1 dr, 92% ee, mp: 76–78 °C. $[\alpha]_D^{25} = -90.5$ ($c: 0.55$, CH_2Cl_2); Determined by UPC² analysis [Daicel chiralcel OX-3, scCO₂/iPrOH = 90/10, 1.5 mL/min, $\lambda = 235.0$ nm, t (major_{isomer}) = 12.42, 12.63 min, t (minor_{isomer}) = 27.99, 38.68 min]; ¹H NMR (400 MHz, CDCl₃) δ 8.19 (d, $J = 1.2$ Hz, 1H), 7.98 – 7.81 (m, 3H), 7.68 (dd, $J = 8.4, 2.0$ Hz, 1H), 7.63 – 7.54 (m, 2H), 7.51 – 7.38 (m, 3H), 7.37 – 7.27 (m, 2H), 4.54 (dd, $J = 9.6, 6.4$ Hz, 1H), 3.88 (s, 3H), 2.81 (dd, $J = 18.8, 9.6$ Hz, 1H), 2.58 (dd, $J = 18.4, 6.4$ Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 174.1, 172.8, 166.6, 133.4, 133.0, 131.2, 130.0, 129.3, 129.2, 129.1, 128.5, 128.2, 127.8, 127.7, 127.5, 127.1, 126.5, 122.4, 115.9, 55.5, 54.7, 47.1, 31.6. HRMS (ESI-FT) calcd for [M+Na]⁺ C₂₄H₁₈N₂O₄Na⁺, m/z: 421.1159, observed: 421.1153. IR: 1752, 1721, 1264, 1194, 817, 731, 703 cm⁻¹.




	Retention Time	Area	% Area
1	12.332	29549603	35.59
2	15.061	28956816	34.88
3	27.596	12262460	14.77
4	38.510	12251330	14.76




	Retention Time	Area	% Area
1	12.419	1234498	3.39
2	14.629	33419784	91.86
3	27.987	252423	0.69
4	38.681	1474426	4.05


Methyl 2-cyano-2-[1-(p-tolyl)-2,5-dioxopyrrolidin-3-yl]-2-phenylacetate (3ab)



White solid, 62% yield, >19:1 dr, 92% ee, mp: 126-130 °C. $[\alpha]_D^{16} = -64.9$ (*c*: 0.60, CH_2Cl_2); Determined by UPC² analysis [Daicel chiralcel OD-3, $\text{scCO}_2/\text{iPrOH} = 90/10$, 1.5 mL/min, $\lambda = 232.0$ nm, *t* (major_{isomer}) = 5.93, 9.49 min, *t* (minor_{isomer}) = 10.91, 12.07 min]; ¹H NMR (400 MHz, CDCl_3) δ 7.71 – 7.61 (m, 2H), 7.52 – 7.43 (m, 3H), 7.31 – 7.26 (d, *J* = 8.4 Hz, 2H), 7.22 – 7.14 (m, 2H), 4.39 (dd, *J* = 9.6, 6.4 Hz, 1H), 3.88 (s, 3H), 2.80 (dd, *J* = 18.4, 9.2 Hz, 1H), 2.53 (dd, *J* = 18.4, 6.4 Hz, 1H), 2.38 (s, 3H). ¹³C NMR (100 MHz, CDCl_3) δ 174.1, 173.0, 166.6, 139.2, 131.1, 130.0, 129.9, 129.8, 128.5, 126.5, 126.3, 115.8, 55.3, 54.6, 47.1, 31.6, 21.3. HRMS (ESI-TOF) calcd for $[\text{M}+\text{Na}]^+$ $\text{C}_{21}\text{H}_{18}\text{N}_2\text{O}_4\text{Na}^+$, *m/z*: 385.1159, observed: 385.1163. IR: 2360, 1751, 1715, 1514, 1245, 1197, 731, 698 cm^{-1} .




	Retention Time	Area	% Area
1	5.949	7711751	39.29
2	9.187	7743878	39.46
3	10.655	2104209	10.72
4	11.832	2066402	10.53




	Retention Time	Area	% Area
1	5.928	8633167	94.42
2	9.491	355083	3.88
3	10.909	129443	1.42
4	12.069	25311	0.28


Methyl 2-cyano-2-[1-(4-methoxyphenyl)-2,5-dioxopyrrolidin-3-yl]-2-phenylacetate (3ac)



White solid, 70% yield, 16:1 dr, 92% ee, mp: 126–130 °C. $[\alpha]_D^{15} = -64.9$ ($c: 0.60, \text{CH}_2\text{Cl}_2$); Determined by UPC² analysis [Daicel chiralcel OD-3, scCO₂/MeOH = 90/10, 1.5 mL/min, $\lambda = 229.0$ nm, t (major_{isomer}) = 6.29, 9.39 min, t (minor_{isomer}) = 11.68, 16.70 min]; ¹H NMR (400 MHz, CDCl₃) δ 7.72 – 7.60 (m, 2H), 7.52 – 7.42 (m, 3H), 7.25 – 7.22 (m, 2H), 7.02 – 6.93 (m, 2H), 4.39 (dd, $J = 9.2, 6.4$ Hz, 1H), 3.88 (s, 3H), 3.82 (s, 3H), 2.80 (dd, $J = 18.4, 9.2$ Hz, 1H), 2.52 (dd, $J = 18.4, 6.4$ Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 174.3, 173.1, 166.6, 159.8, 131.1, 130.0, 129.8, 127.8, 126.5, 123.8, 115.8, 114.6, 55.5, 55.3, 54.6, 47.0, 31.5. HRMS (ESI-FT) calcd for [M+Na]⁺ C₂₁H₁₈N₂O₅Na⁺, m/z: 401.1108, observed: 401.1113. IR: 2361, 1753, 1721, 1514, 1264, 896, 731, 703 cm⁻¹.




	Retention Time	Area	% Area
1	6.356	9692246	40.56
2	9.177	9683538	40.52
3	11.560	2269478	9.50
4	16.247	2253353	9.43




	Retention Time	Area	% Area
1	6.286	23467367	92.70
2	9.341	949059	3.75
3	11.682	124468	0.49
4	16.698	773564	3.06


Methyl 2-cyano-2-[1-(4-ethylphenyl)-2,5-dioxopyrrolidin-3-yl]-2-phenylacetate (3ad)



White solid, 73% yield, >19:1 dr, 93% ee, mp: 132–135 °C. $[\alpha]_D^{17} = -55.6$ (*c*: 0.54, CH_2Cl_2); Determined by UPC² analysis [Daicel chiralcel OJ-3, $\text{scCO}_2/\text{iPrOH} = 95/5$, 1.5 mL/min, $\lambda = 237.0$ nm, *t* (major_{isomer}) = 9.30, 11.18 min, *t* (minor_{isomer}) = 12.41, 14.64 min]; ¹H NMR (400 MHz, CDCl_3) δ 7.71 – 7.61 (m, 2H), 7.52 – 7.44 (m, 3H), 7.30 (d, *J* = 8.4 Hz, 2H), 7.21 (d, *J* = 8.0 Hz, 2H), 4.39 (dd, *J* = 9.2, 6.4 Hz, 1H), 3.87 (s, 3H), 2.80 (dd, *J* = 18.4, 9.2 Hz, 1H), 2.68 (q, *J* = 7.6 Hz, 2H), 2.53 (dd, *J* = 18.8, 6.4 Hz, 1H), 1.24 (t, *J* = 7.6 Hz, 3H). ¹³C NMR (100 MHz, CDCl_3) δ 174.3, 173.1, 166.6, 159.8, 131.1, 130.0, 129.8, 127.8, 126.5, 123.8, 115.8, 114.6, 55.3, 54.6, 47.1, 31.6, 28.6, 15.4. HRMS (ESI-TOF) calcd for $[\text{M}+\text{Na}]^+$ $\text{C}_{22}\text{H}_{20}\text{N}_2\text{O}_4\text{Na}^+$, *m/z*: 399.1315, observed: 399.1314. IR: 2360, 1753, 1721, 1515, 1390, 1264, 731, 703 cm^{-1} .




	Retention Time	Area	% Area
1	8.947	4907363	40.95
2	10.635	4880129	40.72
3	11.790	1125910	9.39
4	13.969	1071735	8.94




	Retention Time	Area	% Area
1	9.299	368282	94.19
2	11.185	14638092	2.37
3	12.414	482305	3.10
4	14.641	52437	0.34


Methyl 2-cyano-2-[1-(4-ethoxyphenyl)-2,5-dioxopyrrolidin-3-yl]-2-phenylacetate (3ae)



White solid, 65% yield, >19:1 dr, 93% ee, mp: 94–98 °C. $[\alpha]_D^{20} = -56.1$ ($c: 0.54$, CH_2Cl_2); Determined by UPC² analysis [Daicel chiralcel OJ-3, $\text{scCO}_2/\text{MeOH} = 90/10$, 1.5 mL/min, $\lambda = 235.0$ nm, t (major_{isomer}) = 7.92, 8.83 min, t (minor_{isomer}) = 14.22, 15.17 min; ¹H NMR (400 MHz, CDCl_3) δ 7.70 – 7.47 (m, 2H), 7.45 – 7.31 (m, 3H), 7.17 – 7.05 (m, 2H), 6.94 – 6.79 (m, 2H), 4.31 (dd, $J = 9.2, 6.4$ Hz, 1H), 3.97 (q, $J = 7.2$ Hz, 1H), 3.80 (s, 3H), 2.72 (dd, $J = 18.8, 9.6$ Hz, 1H), 2.44 (dd, $J = 18.8, 6.4$ Hz, 1H), 1.34 (t, $J = 7.2$ Hz, 3H). ¹³C NMR (100 MHz, CDCl_3) δ 174.3, 173.1, 166.6, 159.2, 131.1, 130.0, 129.8, 127.7, 126.5, 123.6, 115.8, 115.1, 63.8, 55.3, 54.6, 47.0, 31.5, 14.7. HRMS (ESI-TOF) calcd for $[\text{M}+\text{Na}]^+$ $\text{C}_{22}\text{H}_{20}\text{N}_2\text{O}_5\text{Na}^+$, m/z: 415.1264, observed: 415.1263. IR: 1719, 1521, 1264, 731, 702 cm^{-1} .




	Retention Time	Area	% Area
1	7.990	3690318	47.46
2	8.805	3703534	47.63
3	14.247	192994	2.48
4	15.174	188458	2.42




	Retention Time	Area	% Area
1	7.922	11100691	93.58
2	8.828	372677	3.14
3	14.220	38197	0.32
4	15.166	350948	2.96


Methyl 2-cyano-2-[1-(4-isopropylphenyl)-2,5-dioxopyrrolidin-3-yl]-2-phenylacetate (3af)



White solid, 72% yield, >19:1 dr, 92% ee, mp: 165–170 °C. $[\alpha]_D^{16} = -51.5$ (*c*: 0.52, CH_2Cl_2); Determined by UPC² analysis [Daicel chiralcel OD-3, $\text{scCO}_2/\text{PrOH} = 90/10$, 1.5 mL/min, $\lambda = 244.0$ nm, *t* (major_{isomer}) = 5.26, 9.31 min, *t* (minor_{isomer}) = 8.46, 11.57 min]; ¹H NMR (400 MHz, CDCl_3) δ 7.68 – 7.62 (m, 2H), 7.52 – 7.44 (m, 3H), 7.33 (d, *J* = 8.0 Hz, 2H), 7.24 – 7.18 (m, 2H), 4.39 (dd, *J* = 9.6, 6.4 Hz, 1H), 3.87 (s, 3H), 3.00 – 2.88 (m, 1H), 2.80 (dd, *J* = 18.8, 9.6 Hz, 1H), 2.53 (dd, *J* = 18.8, 6.4 Hz, 1H), 1.25 (d, *J* = 6.8 Hz, 6H). ¹³C NMR (101 MHz, CDCl_3) δ 174.2, 173.0, 166.6, 150.0, 131.1, 130.0, 129.8, 128.7, 127.4, 126.5, 126.3, 115.8, 55.3, 54.6, 54.6, 47.1, 34.0, 31.6, 23.9. HRMS (ESI-FT) calcd for $[\text{M}+\text{Na}]^+$ $\text{C}_{23}\text{H}_{22}\text{N}_2\text{O}_4\text{Na}^+$, *m/z*: 413.1472, observed: 413.1476. IR: 2961, 1751, 1716, 1514, 1391, 1245, 734, 700 cm^{-1} .




	Retention Time	Area	% Area
1	5.318	7845279	50.21
2	8.448	40555	0.26
3	8.946	7693338	49.23
4	11.563	47147	0.30




	Retention Time	Area	% Area
1	5.258	12081664	93.12
2	8.461	412056	3.18
3	9.311	440869	3.40
4	11.568	39094	0.30

Methyl 2-cyano-2-[1-(4-fluorophenyl)-2,5-dioxopyrrolidin-3-yl]-2-phenylacetate (3ag)




White solid, 78% yield, 19:1 dr, 92% ee, mp: 96–98 °C. $[\alpha]_D^{16} = -47.9$ (*c*: 0.24, CH_2Cl_2); Determined by UPC² analysis [Daicel chiralcel OD-3, $\text{scCO}_2/\text{PrOH} = 94/6$, 1.5 mL/min, $\lambda = 227.0$ nm, *t* (major_{isomer}) = 7.12, 14.71 min, *t* (minor_{isomer}) = 13.20, 21.37 min]; ¹H NMR (400 MHz, CDCl_3) δ 7.69 – 7.60 (m, 2H), 7.53 – 7.43 (m, 3H), 7.35 – 7.27 (m, 2H),

7.21 – 7.11 (m, 2H), 4.41 (dd, *J* = 9.2, 6.4 Hz, 1H), 3.89 (s, 3H), 2.82 (dd, *J* = 18.4, 9.2 Hz, 1H), 2.54 (dd, *J* = 18.4, 6.4 Hz, 1H). ¹³C NMR (100 MHz, CDCl_3) δ 173.9, 172.7, 166.6, 163.7 (*J* = 247.7 Hz, 1C), 130.9, 130.1, 129.8, 128.5 (*J* = 8.8 Hz, 1C), 127.1 (*J* = 3.2 Hz, 1C), 126.5, 116.5 (*J* = 22.9 Hz, 1C), 115.8, 55.3, 54.7, 47.0, 31.6. ¹⁹F NMR (376 MHz, CDCl_3) δ -110.5 (s, 1F). HRMS (ESI-FT) calcd for $[\text{M}+\text{Na}]^+$ $\text{C}_{20}\text{H}_{15}\text{FN}_2\text{O}_4\text{Na}^+$, *m/z*: 389.0908, observed: 389.0898. IR: 1750, 1717, 1510, 1392, 1241, 1193, 1017, 969, 837, 730, 698 cm^{-1} .




	Retention Time	Area	% Area
1	7.694	6604763	42.97
2	13.278	1197234	7.79
3	14.629	6418296	41.76
4	20.938	1149061	7.48




	Retention Time	Area	% Area
1	7.120	16181493	93.55
2	13.203	475743	2.75
3	14.713	593126	3.43
4	21.371	46098	0.27


Methyl 2-[1-(4-chlorophenyl)-2,5-dioxopyrrolidin-3-yl]-2-cyano-2-phenylacetate (3ah)



White solid, 68% yield, 16:1 dr, 93% ee, mp: 59–62 °C. $[\alpha]_D^{16} = -56.4$ (*c*: 0.39, CH_2Cl_2); Determined by UPC² analysis [Daicel chiralcel OD-3, scCO₂/PrOH = 90/10, 1.5 mL/min, $\lambda = 232.0$ nm, t (major_{isomer}) = 6.14, 10.87 min, t (minor_{isomer}) = 10.14, 15.63 min]; ¹H NMR (400 MHz, CDCl_3) δ 7.68 – 7.61 (m, 2H), 7.51 – 7.42 (m, 5H), 7.30 – 7.24 (m, 2H), 4.40 (dd, *J* = 9.6, 6.4 Hz, 1H), 3.89 (s, 3H), 2.82 (dd, *J* = 18.8, 9.6 Hz, 1H), 2.54 (dd, *J* = 18.8, 6.4 Hz, 1H). ¹³C NMR (100 MHz, CDCl_3) δ 173.7, 172.5, 166.5, 135.0, 130.9, 130.1, 129.8, 129.6, 129.5, 127.8, 126.5, 125.7, 115.8, 55.3, 54.7, 47.1, 31.6. HRMS (ESI-FT) calcd for $[\text{M}+\text{Na}]^+$ $\text{C}_{20}\text{H}_{15}\text{ClN}_2\text{O}_4\text{Na}^+$, m/z: 405.0613, 407.0585; observed: 405.0615, 407.0585. IR: 1749, 1710, 1493, 1388, 1244, 1192, 1092, 1017, 830, 730, 696 cm^{-1} .




	Retention Time	Area	% Area
1	6.203	13525704	39.71
2	10.002	3471574	10.19
3	10.619	13582259	39.87
4	15.374	3484799	10.23




	Retention Time	Area	% Area
1	6.138	31880220	93.26
2	10.140	1000078	2.93
3	10.886	1105004	3.23
4	15.633	197396	0.58


Methyl 2-[1-(4-bromophenyl)-2,5-dioxopyrrolidin-3-yl]-2-cyano-2-phenylacetate (3ai)



White solid, 65% yield, 16:1 dr, 93% ee, mp: 55–58 °C. $[\alpha]_D^{16} = -44.0$ (*c*: 0.54, CH_2Cl_2); Determined by UPC² analysis [Daicel chiralcel OD-3, $\text{scCO}_2/\text{PrOH} = 92/8$, 1.5 mL/min, $\lambda = 231.0$ nm, t (major_{isomer}) = 10.21, 19.38 min, t (minor_{isomer}) = 17.43, 27.76 min]; ¹H NMR (400 MHz, CDCl_3) δ 7.68 – 7.57 (m, 4H), 7.52 – 7.44 (m, 3H), 7.25 – 7.17 (m, 2H), 4.40 (dd, *J* = 9.2, 6.4 Hz, 1H), 3.89 (s, 3H), 2.81 (dd, *J* = 18.8, 9.6 Hz, 1H), 2.54 (dd, *J* = 18.4, 6.4 Hz, 1H). ¹³C NMR (100 MHz, CDCl_3) δ 173.6, 172.4, 166.5, 132.5, 130.9, 130.2, 130.1, 129.8, 128.0, 126.5, 123.0, 115.8, 55.3, 54.7, 47.1, 31.6. HRMS (ESI-FT) calcd for $[\text{M}+\text{Na}]^+$ $\text{C}_{20}\text{H}_{15}\text{BrN}_2\text{O}_4\text{Na}^+$, m/z: 449.0107, 451.0087; observed: 449.0114, 451.0095. IR: 1749, 1715, 1490, 1386, 1244, 1179, 1070, 1014, 969, 826, 731, 695 cm^{-1} .




	Retention Time	Area	% Area
1	9.979	9102482	47.13
2	17.410	546893	2.83
3	18.322	9098166	47.11
4	27.006	566656	2.93




	Retention Time	Area	% Area
1	10.212	21753915	94.85
2	17.431	357193	1.56
3	19.383	756187	3.30
4	27.760	68318	0.30


Methyl 2-[1-(4-iodophenyl)-2,5-dioxopyrrolidin-3-yl]-2-cyano-2-phenylacetate (3aj)



White solid, 78% yield, 16:1 dr, 93% ee, mp: 76–79 °C. $[\alpha]_D^{18} = -34.6$ (c : 0.18, CH_2Cl_2); Determined by UPC² analysis [Daicel chiralcel OD-3, scCO₂/PrOH = 90/10, 1.5 mL/min, $\lambda = 227.0$ nm, t (major_{isomer}) = 10.63, 19.32 min, t (minor_{isomer}) = 17.79, 27.63 min]; ¹H NMR (400 MHz, CDCl_3) δ 7.82–7.76 (m, 2H), 7.70–7.57 (m, 2H), 7.51–7.43 (m, 3H), 7.14–7.00 (m, 2H), 4.40 (dd, $J = 9.2, 6.4$ Hz, 1H), 3.88 (s, 3H), 2.80 (dd, $J = 18.8, 9.6$ Hz, 1H), 2.52 (dd, $J = 18.4, 6.4$ Hz, 1H). ¹³C NMR (100 MHz, CDCl_3) δ 173.7, 172.4, 166.5, 138.5, 130.9, 130.9, 130.1, 129.8, 128.2, 126.5, 115.8, 94.7, 55.3, 54.7, 47.1, 31.6. HRMS (ESI-FT) calcd for $[\text{M}+\text{Na}]^+$ $\text{C}_{20}\text{H}_{15}\text{IN}_2\text{O}_4\text{Na}^+$, m/z: 496.9969; observed: 496.9974. IR: 2360, 1752, 1722, 1487, 1386, 1264, 1194, 731, 703 cm⁻¹.




	Retention Time	Area	% Area
1	10.342	6521672	39.47
2	17.755	1395249	8.44
3	18.437	6860454	41.52
4	26.656	1744743	10.56




	Retention Time	Area	% Area
1	10.634	9366577	92.72
2	17.786	365453	3.62
3	19.319	347651	3.44
4	27.630	22396	0.22


Methyl 2-cyano-2-[1-(2-fluorophenyl)-2,5-dioxopyrrolidin-3-yl]-2-phenylacetate (3ak)



White solid, 73% yield, 11:1 dr, 93% ee, mp: 148–152 °C. $[\alpha]_D^{15} = -50.2$ (*c*: 0.51, CH_2Cl_2); Determined by UPC² analysis [Daicel chiralcel OX-3, scCO₂/MeOH = 90/10, 1.5 mL/min, $\lambda = 230.0$ nm, t (major_{isomer}) = 3.31, 3.68 min, t (minor_{isomer}) = 5.68, 6.78 min]; ¹H NMR (400 MHz, CDCl_3) δ 7.72 – 7.60 (m, 2H), 7.52 – 7.40 (m, 4H), 7.32 – 7.20 (m, 3H), 4.55 – 4.36 (m, 1H), 3.88 (s, 3H), 3.00 – 2.52 (m, 2H). ¹³C NMR (100 MHz, CDCl_3) δ 173.2, 171.9, 166.5, 164.0, 158.6 ($J = 250.0$ Hz, 1C), 131.5 ($J = 8.0$ Hz, 1C), 131.1, 130.0, 129.8 ($J = 22.9$ Hz, 1C), 126.5, 124.9, 119.0 ($J = 13.2$ Hz, 1C), 116.8, 116.7, 54.7, 54.6, 47.3, 31.7. ¹⁹F NMR (376 MHz, CDCl_3) δ -117.8, -119.9 (d, 1F). HRMS (ESI-FT) calcd for $[\text{M}+\text{Na}]^+$ $\text{C}_{20}\text{H}_{15}\text{FN}_2\text{O}_4\text{Na}^+$, m/z: 389.0908, observed: 389.0890. IR: 1750, 1721, 1504, 1388, 1240, 1194, 817, 761, 730, 680 cm^{-1} .




	Retention Time	Area	% Area
1	3.427	4598266	39.77
2	3.809	4628572	40.04
3	5.762	1171740	10.14
4	6.845	1162164	10.05




	Retention Time	Area	% Area
1	3.309	270453	3.23
2	3.680	7685474	91.78
3	5.676	57154	0.68
4	6.785	360956	4.31


Methyl 2-cyano-2-(2,5-dioxo-1-(o-tolyl)pyrrolidin-3-yl)-2-phenylacetate (3al)



White solid, 85% yield, >19:1 dr, 93% ee, mp: 152–155 °C. $[\alpha]_D^{19} = -51.5$ (*c*: 0.39, CH_2Cl_2); Determined by UPC² analysis [Daicel chiralcel OD-3, $\text{scCO}_2/\text{iPrOH}$ = 92/8, 1.0 mL/min, λ = 219.0 nm, *t* (major_{isomer}) = 9.35, 16.48 min, *t* (minor_{isomer}) = 14.82, 21.88 min]; ¹H NMR (400 MHz, CDCl_3) δ 7.75 – 7.61 (m, 2H), 7.55 – 7.42 (m, 3H), 7.38 – 7.27 (m, 3H), 7.21 – 7.00 (m, 1H), 4.52 – 4.36 (m, 1H, rotamer), 3.87 (s, 3H), 2.93 – 2.74 (m, 1H, rotamer), 2.66 – 2.49 (m, 1H, rotamer), 2.25 and 2.16 (s, 3H, rotamer). ¹³C NMR (100 MHz, CDCl_3) δ 174.0 and 173.9 (rotamer), 172.8 and 172.7 (rotamer), 166.6, 136.2, 135.3, 131.4, 131.1, 130.3 and 130.3 (rotamer), 130.0 and 130.0 (rotamer), 129.9 and 129.8 (rotamer), 128.2 and 127.7 (rotamer), 127.3 and 126.9 (rotamer), 126.6 and 126.5 (rotamer), 116.1 and 115.8 (rotamer), 55.5 and 55.1 (rotamer), 54.6, 47.7 and 47.1 (rotamer), 31.8 and 31.7 (rotamer), 17.9 and 17.7 (rotamer). HRMS (ESI-FT) calcd for $[\text{M}+\text{Na}]^+$ $\text{C}_{21}\text{H}_{18}\text{N}_2\text{O}_4\text{Na}^+$, *m/z*: 385.1159, observed: 385.1164. IR: 1721, 1264, 896, 731, 703 cm^{-1} .




	Retention Time	Area	% Area
1	9.415	6440618	42.37
2	14.947	997951	6.57
3	16.058	6594736	43.38
4	21.362	1167692	7.68




	Retention Time	Area	% Area
1	9.350	36869712	95.46
2	14.822	578301	1.50
3	16.477	1103569	2.86
4	21.880	71150	0.18


Methyl 2-cyano-2-[1-(3-fluorophenyl)-2,5-dioxopyrrolidin-3-yl]-2-phenylacetate (3am)



White solid, 65% yield, 16:1 dr, 91% ee, mp: 119–122 °C. $[\alpha]_D^{16} = -72.5$ (*c*: 0.34, CH_2Cl_2); Determined by UPC² analysis [Daicel chiralcel OD-3, scCO₂/PrOH = 90/10, 1.5 mL/min, $\lambda = 235.0$ nm, t (major_{isomer}) = 4.06, 6.37 min, t (minor_{isomer}) = 5.95, 8.44 min]; ¹H NMR (400 MHz, CDCl_3) δ 7.70 – 7.61 (m, 2H), 7.53 – 7.39 (m, 4H), 7.18 – 7.06 (m, 3H), 4.41 (dd, *J* = 9.2, 6.4 Hz, 1H), 3.89 (s, 3H), 2.83 (dd, *J* = 18.8, 9.6 Hz, 1H), 2.55 (dd, *J* = 18.4, 6.4 Hz, 1H). ¹³C NMR (100 MHz, CDCl_3) δ 173.6, 172.3, 166.5, 163.9 (*J* = 246.5 Hz, 1C), 132.4 (*J* = 10.1 Hz, 1C), 130.9, 130.5 (*J* = 8.8 Hz, 1C), 130.1, 129.8, 126.5, 122.2 (*J* = 3.3 Hz, 1C), 116.3 (*J* = 20.6 Hz, 1C), 115.8, 114.2 (*J* = 24.4 Hz, 1C), 55.3, 54.7, 47.1, 31.6. ¹⁹F NMR (376 MHz, CDCl_3) δ -110.7 (s, 1F). HRMS (ESI-FT) calcd for $[\text{M}+\text{Na}]^+$ $\text{C}_{20}\text{H}_{15}\text{FN}_2\text{O}_4\text{Na}^+$, m/z: 389.0908, observed: 389.0898. IR: 1750, 1719, 1599, 1492, 1452, 1384, 1237, 1177, 843, 775, 730, 704 cm^{-1} .




	Retention Time	Area	% Area
1	4.058	7868603	39.94
2	5.838	34203507	9.19
3	6.288	35086322	40.97
4	8.394	8487091	9.91




	Retention Time	Area	% Area
1	4.058	9099367	90.66
2	5.946	457321	4.56
3	6.370	408199	4.07
4	8.443	72159	0.72


Methyl 2-(1-benzyl-2,5-dioxopyrrolidin-3-yl)-2-cyano-2-phenylacetate (3an)



Colorless oily, 36% yield, 7:1 dr, 72% ee, $[\alpha]_D^{19} = -11.6$ ($c: 0.63, \text{CH}_2\text{Cl}_2$); Determined by UPC² analysis [Daicel chiralcel OX-3, scCO₂/MeOH = 95/5, 1.5 mL/min, $\lambda = 214.0$ nm, t (major_{isomer}) = 9.37, 14.39 min, t (minor_{isomer}) = 16.81, 23.99 min]; ¹H NMR (400 MHz, CDCl₃) δ 7.63 – 7.54 (m, 2H), 7.46 – 7.41 (m, 3H), 7.39 – 7.34 (m, 2H), 7.33 – 7.27 (m, 3H), 4.70 (dd, $J = 14.0, 30.4$ Hz, 2H), 4.22 (dd, $J = 9.2, 7.6$ Hz, 1H), 3.89 (s, 3H), 2.61 (dd, $J = 18.4, 9.6$ Hz, 1H), 2.36 (dd, $J = 18.4, 6.8$ Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 174.5, 173.4, 166.6, 135.0, 131.1, 129.9, 129.7, 128.7, 128.7, 128.2, 126.4, 115.7, 54.8, 54.6, 47.0, 42.9, 31.5. HRMS (ESI-FT) calcd for [M+Na]⁺ C₂₁H₁₈N₂O₄Na⁺, m/z: 385.1159, observed: 385.1162. IR: 1751, 1711, 1399, 1264, 1169, 817, 731, 701 cm⁻¹.




	Retention Time	Area	% Area
1	9.764	7334510	40.88
2	14.412	7326609	40.83
3	16.989	1630771	9.09
4	23.746	1651163	9.20




	Retention Time	Area	% Area
1	9.366	26410074	80.15
2	14.391	4247999	12.89
3	16.812	1636591	4.97
4	23.990	654148	1.99


Methyl 2-cyano-2-(1-methyl-2,5-dioxopyrrolidin-3-yl)-2-phenylacetate (3ao)



Colorless oily, 54% yield, 5:1 dr, 50% ee, $[\alpha]_D^{19} = -11.1$ ($c: 0.21, \text{CH}_2\text{Cl}_2$); Determined by UPC² analysis [Daicel chiralcel OX-3, scCO₂/PrOH = 85/15, 1.5 mL/min, $\lambda = 224.0$ nm, t (major_{isomer}) = 2.00, 2.38 min, t (minor_{isomer}) = 2.98, 3.67 min]; ¹H NMR (400 MHz, CDCl₃) δ 7.60 – 7.32 (m, 5H), 4.15 (dd, $J = 9.2, 6.4$ Hz, 1H), 3.83 (s, 3H), 2.99 (s, 3H), 2.57 (dd, $J = 18.4, 9.2$ Hz, 1H), 2.30 (dd, $J = 18.4, 6.4$ Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 173.8, 172.7, 165.6, 130.1, 128.9, 128.7, 125.4, 114.7, 53.9, 53.6, 46.1, 30.4, 24.2. HRMS (ESI-FT) calcd for [M+Na]⁺ C₁₅H₁₄N₂O₄Na⁺, m/z: 309.0846, observed: 309.0845. IR: 1747, 1701, 1436, 1384, 1284, 1241, 1118, 978, 731, 695 cm⁻¹.




	Retention Time	Area	% Area
1	2.060	3633845	37.84
2	2.424	3638673	37.89
3	3.000	1159924	12.08
4	3.648	1171882	12.20




	Retention Time	Area	% Area
1	1.999	3150944	65.26
2	2.379	1035094	21.44
3	2.978	377262	7.81
4	3.673	264909	5.49


Di-tert-butyl 1-(1-cyano-2-methoxy-2-oxo-1-phenylethyl)hydrazine-1,2-dicarboxylate (5aa)



Colorless oily, 66% yield, 0% ee; Determined by HPLC analysis [Daicel chiralcel IB, *n*-Hexane /*i*PrOH = 95/5, 1.0 mL/min, λ = 220 nm, t_1 = 13.98 min, t_2 = 16.44 min]; ^1H NMR (400 MHz, CDCl_3) δ 7.83 – 7.55 (m, 2H), 7.48 – 7.33 (m, 3H), 6.30 – 5.87 (m, 1H), 3.88 – 3.75 (m, 3H), 1.58 – 1.23 (m, 18H). ^{13}C NMR (100 MHz, CDCl_3) δ 164.9, 164.7, 153.0, 129.6/129.2(rotamer), 129.1/129.0(rotamer), 128.4, 128.2/127.9 (rotamer), 127.2/127.0(rotamer), 114.6, 82.2, 80.6, 76.3, 53.3, 27.1, 27.0, 26.9. HRMS (ESI-FT) calcd for $[\text{M}+\text{Na}]^+$ $\text{C}_{20}\text{H}_{27}\text{N}_3\text{O}_6\text{Na}^+$, m/z: 428.1792, observed: 428.1797. IR: 1739, 1264, 1153, 907, 731, 705 cm^{-1} .




	Retention Time	Area	% Area
1	13.964	23149540	49.85
2	16.479	23285563	50.15




	Retention Time	Area	% Area
1	13.978	57670214	49.40
2	16.439	59078987	50.60


Methyl 2-(1-benzyl-3-((tert-butoxycarbonyl)amino)-2-oxoindolin-3-yl)-2-cyano-2-phenylacetate (6aa)



Colorless oily, 69% yield, 10:1 dr, 22% ee; Determined by HPLC analysis [Daicel chiralcel ADH, *n*-Hexane /*i*PrOH = 80/20, 1.0 mL/min, λ = 228 nm, t (major_{isomer}) = 13.10, 22.61 min, t (minor_{isomer}) = 7.55, 9.33 min]; ¹H NMR (400 MHz, CDCl₃) δ 7.43 – 7.32 (m, 1H), 7.27 – 7.21 (m, 2H), 7.20 – 7.06 (m, 6H), 6.97 – 6.83 (m, 1H), 6.79 (t, J = 7.6 Hz, 1H), 6.57 (s, 1H), 6.50 (d, J = 7.6 Hz, 1H), 4.92 – 4.76 (m, 1H), 4.72 – 4.55 (m, 1H), 3.83 (s, 3H), 1.17 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 173.2, 166.6, 153.9, 144.2, 135.1, 130.3, 129.8, 129.0, 128.6, 128.3, 128.0, 127.5, 127.4, 125.8, 124.5, 122.3, 115.0, 109.5, 80.9, 65.8, 57.9, 54.7, 44.6, 28.0. HRMS (ESI-FT) calcd for [M+Na]⁺ C₃₀H₂₉N₃O₅Na⁺, m/z: 534.1999, observed: 534.1993. IR: 1724, 1611, 1486, 1263, 1241, 1162, 906, 731, 703 cm⁻¹.




	Retention Time	Area	% Area
1	7.639	3266876	9.33
2	9.373	3331704	9.51
3	13.603	14410318	41.15
4	23.505	14011513	40.01





	Retention Time	Area	% Area
1	7.548	468756	4.25
2	9.326	562038	5.10
3	13.096	3862692	35.03
4	22.609	6133507	55.62

8. NMR spectra


G-5 • HBr




3aa


3ba

3ca




3ea







3fa





3ga




3ha

3ia







3ja





3ka





3la




3ma


3ab


3ac


3ad

3ae


3af




3ag




3ah




3ai




3aj




3ak




-117.819
~ -119.897





3ak




3al




3am




3an




3ao



5aa




6aa



9. X-ray crystal structure of the product 3aa





The colourless and block-shape crystals were selected and mounted for the single-crystal X-ray diffraction. The data set was collected by a Bruker D8 Venture Photon II at 241K equipped with micro-focus Cu radiation source ($K_{\alpha} = 1.54178\text{\AA}$). The structure solution was solved and refinement was processed by SHELXTL (version 6.14) program package^{2a,2b}. The structure was analyzed by ADDSYM routine in PLATON suite and no higher symmetry was suggested^{2c}.











CCDC: 1901489





10. Copies of the CD spectra of the products 3




(*S,R*)-3aa (standard)









































11. References

- (a) Z. P. Yu, X. H. Liu, L. Zhou, L. L. Lin and X. M. Feng, *Angew. Chem. Int. Ed.*, 2009, **48**, 5195; (b) S. X. Dong, X. H. Liu, X. H. Chen, F. Mei, Y. L. Zhang, B. Gao, L. L. Lin and X. M. Feng, *J. Am. Chem. Soc.*, 2010, **132**, 10650; (c) S. X. Dong, X. H. Liu, Y. L. Zhang, L. L. Lin and X. M. Feng, *Org. Lett.*, 2011, **13**, 5060; (d) S. Ruan, X. B. Lin, L. H. Xie, L. L. Lin, X. M. Feng and X. H. Liu, *Org. Chem. Front.*, 2018, **5**, 32.
- (a) G. M. Sheldrick, *Acta Cryst.*, 2008, **A64**, 112; (b) G. M. Sheldrick, *Acta Cryst.*, 2015, **A71**, 3; (c) A. L. Spek, *J. Appl. Cryst.*, 2003, **36**, 7.